Editas Medicine Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
/ 
Frequently asked questions
To buy Editas Medicine Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Editas Medicine Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Editas Medicine Inc. is EDIT:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Editas Medicine Inc. has its primary listing on NASDAQ. You can trade Editas Medicine Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Editas Medicine Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Editas Medicine Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Editas Medicine Inc..